NON-ANTIBIOTIC INTERVENTION OF CHLAMYDIAL INFECTION

Huizhou Fan (Inventor)

Research output: Innovation

Abstract

Invention Summary:

Chlamydial infection is caused by Chlamydia trachomatis bacterium and is one of the most common sexually transmitted infections worldwide. As per U.S. Centers for Disease Control and Prevention estimates, there are 4 million new cases of Chlamydial infections each year. Chlamydial infection often results in abnormal discharge from female and male sexual organs and pain while urinating. If left untreated, the infection may spread to other organs of the body causing pelvic inflammatory disease (PID) in women and epidydimitis in men, inflamed rectum and inflammation of the eye. Approximately 600 million people worldwide suffer C. trachomatis eye infections and 20 million are blinded as a result of the infection. Current treatment methods include the use of antibiotics such as azithromycin, doxycycline, erythromycin, or ofloxacin. The use of prescription antiobiotics poses the risk of developing antibiotic resistance and disruption of normal microbial floras. Thus, there is a long felt medical need for alternative treatment strategies that overcome the aforementioned limitations.

The present technology represents a novel strategy to effectively prevent and eliminate C. trachomatis infection. The current invention disclosed new methods to prevent and treat Chlamydia infection using certain metalloprotease inhibitors. Topical composition containing such metalloprotease inhibitors can be applied to the infected site or a site likely to be infected. Topical composition containing such metalloprotease inhibitors can also be used to coat barrier contraceptive devices for reducing the risk of Chlamydia infection.

Market Applications:

Prevention and treatment of chlamydia infection

Advantages:
  • Non-antibiotic treatment
  • Ready to be applied to the infected sites or sites likely to be infected
  • Specific to Chlamydia infection, normal microbial flora will not be destroyed

Intellectual Property & Development Status:

  • United States patent number US 7,863,335 B2 granted on January 4, 2011
  • Published PCT application: PCT/US2005/026333
Original languageEnglish (US)
StatePublished - May 2014

Fingerprint

Chlamydia Infections
Anti-Bacterial Agents
Chlamydia trachomatis
Metalloproteases
Infection
Contraceptive Devices
Intellectual Property
Eye Infections
Pelvic Inflammatory Disease
Azithromycin
Ofloxacin
Doxycycline
Erythromycin
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Microbial Drug Resistance
Sexually Transmitted Diseases
Rectum
Prescriptions
Inflammation

Keywords

  • Infectious Disease/Immunology
  • OBGYN
  • Small Molecules

Cite this

@misc{48db6a4cb4874adeafe4a9d7378b2d04,
title = "NON-ANTIBIOTIC INTERVENTION OF CHLAMYDIAL INFECTION",
abstract = "Invention Summary: Chlamydial infection is caused by Chlamydia trachomatis bacterium and is one of the most common sexually transmitted infections worldwide. As per U.S. Centers for Disease Control and Prevention estimates, there are 4 million new cases of Chlamydial infections each year. Chlamydial infection often results in abnormal discharge from female and male sexual organs and pain while urinating. If left untreated, the infection may spread to other organs of the body causing pelvic inflammatory disease (PID) in women and epidydimitis in men, inflamed rectum and inflammation of the eye. Approximately 600 million people worldwide suffer C. trachomatis eye infections and 20 million are blinded as a result of the infection. Current treatment methods include the use of antibiotics such as azithromycin, doxycycline, erythromycin, or ofloxacin. The use of prescription antiobiotics poses the risk of developing antibiotic resistance and disruption of normal microbial floras. Thus, there is a long felt medical need for alternative treatment strategies that overcome the aforementioned limitations. The present technology represents a novel strategy to effectively prevent and eliminate C. trachomatis infection. The current invention disclosed new methods to prevent and treat Chlamydia infection using certain metalloprotease inhibitors. Topical composition containing such metalloprotease inhibitors can be applied to the infected site or a site likely to be infected. Topical composition containing such metalloprotease inhibitors can also be used to coat barrier contraceptive devices for reducing the risk of Chlamydia infection. Market Applications: Prevention and treatment of chlamydia infection Advantages: Non-antibiotic treatment Ready to be applied to the infected sites or sites likely to be infected Specific to Chlamydia infection, normal microbial flora will not be destroyed Intellectual Property & Development Status: United States patent number US 7,863,335 B2 granted on January 4, 2011 Published PCT application: PCT/US2005/026333",
keywords = "Infectious Disease/Immunology, OBGYN, Small Molecules",
author = "Huizhou Fan",
year = "2014",
month = "5",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - NON-ANTIBIOTIC INTERVENTION OF CHLAMYDIAL INFECTION

AU - Fan, Huizhou

PY - 2014/5

Y1 - 2014/5

N2 - Invention Summary: Chlamydial infection is caused by Chlamydia trachomatis bacterium and is one of the most common sexually transmitted infections worldwide. As per U.S. Centers for Disease Control and Prevention estimates, there are 4 million new cases of Chlamydial infections each year. Chlamydial infection often results in abnormal discharge from female and male sexual organs and pain while urinating. If left untreated, the infection may spread to other organs of the body causing pelvic inflammatory disease (PID) in women and epidydimitis in men, inflamed rectum and inflammation of the eye. Approximately 600 million people worldwide suffer C. trachomatis eye infections and 20 million are blinded as a result of the infection. Current treatment methods include the use of antibiotics such as azithromycin, doxycycline, erythromycin, or ofloxacin. The use of prescription antiobiotics poses the risk of developing antibiotic resistance and disruption of normal microbial floras. Thus, there is a long felt medical need for alternative treatment strategies that overcome the aforementioned limitations. The present technology represents a novel strategy to effectively prevent and eliminate C. trachomatis infection. The current invention disclosed new methods to prevent and treat Chlamydia infection using certain metalloprotease inhibitors. Topical composition containing such metalloprotease inhibitors can be applied to the infected site or a site likely to be infected. Topical composition containing such metalloprotease inhibitors can also be used to coat barrier contraceptive devices for reducing the risk of Chlamydia infection. Market Applications: Prevention and treatment of chlamydia infection Advantages: Non-antibiotic treatment Ready to be applied to the infected sites or sites likely to be infected Specific to Chlamydia infection, normal microbial flora will not be destroyed Intellectual Property & Development Status: United States patent number US 7,863,335 B2 granted on January 4, 2011 Published PCT application: PCT/US2005/026333

AB - Invention Summary: Chlamydial infection is caused by Chlamydia trachomatis bacterium and is one of the most common sexually transmitted infections worldwide. As per U.S. Centers for Disease Control and Prevention estimates, there are 4 million new cases of Chlamydial infections each year. Chlamydial infection often results in abnormal discharge from female and male sexual organs and pain while urinating. If left untreated, the infection may spread to other organs of the body causing pelvic inflammatory disease (PID) in women and epidydimitis in men, inflamed rectum and inflammation of the eye. Approximately 600 million people worldwide suffer C. trachomatis eye infections and 20 million are blinded as a result of the infection. Current treatment methods include the use of antibiotics such as azithromycin, doxycycline, erythromycin, or ofloxacin. The use of prescription antiobiotics poses the risk of developing antibiotic resistance and disruption of normal microbial floras. Thus, there is a long felt medical need for alternative treatment strategies that overcome the aforementioned limitations. The present technology represents a novel strategy to effectively prevent and eliminate C. trachomatis infection. The current invention disclosed new methods to prevent and treat Chlamydia infection using certain metalloprotease inhibitors. Topical composition containing such metalloprotease inhibitors can be applied to the infected site or a site likely to be infected. Topical composition containing such metalloprotease inhibitors can also be used to coat barrier contraceptive devices for reducing the risk of Chlamydia infection. Market Applications: Prevention and treatment of chlamydia infection Advantages: Non-antibiotic treatment Ready to be applied to the infected sites or sites likely to be infected Specific to Chlamydia infection, normal microbial flora will not be destroyed Intellectual Property & Development Status: United States patent number US 7,863,335 B2 granted on January 4, 2011 Published PCT application: PCT/US2005/026333

KW - Infectious Disease/Immunology

KW - OBGYN

KW - Small Molecules

UR - http://rutgers.technologypublisher.com/tech/NON-ANTIBIOTIC_INTERVENTION_OF_CHLAMYDIAL_INFECTION

M3 - Innovation

ER -